Peters Jessica T, Garwood Candice L, Lepczyk Marybeth
Department of Pharmacy Practice, Wayne State University, Eugene Applebaum College of Pharmacy and Health Sciences, Detroit, Michigan 48201, USA.
Am J Geriatr Pharmacother. 2008 Mar;6(1):28-32. doi: 10.1016/j.amjopharm.2008.03.001.
There have been a number of published reports of central nervous system (CNS) adverse effects with statins.
A 79-year-old woman developed paranoia, anxiety, and behavioral changes approximately 2.5 weeks after starting atorvastatin 10 mg/d. The patient had no other medication changes at this time. After 2 months of therapy, the patient discontinued atorvastatin, and her symptoms fully resolved after 4 days.
This is the first case report, to our knowledge, describing paranoia as one of the symptoms associated with statin therapy. Our report suggests an adverse reaction due to the initiation of atorvastatin via the temporal relationship between the start of atorvastatin and symptom onset, as well as termination of therapy and subsequent symptom disappearance. Use of the Naranjo adverse drug reaction probability scale to assess causality revealed a "probable" association (score, 5) for this adverse event. This report emphasizes the possibility of paranoia as a CNS adverse effect due to statin therapy. Statins are frequently used in older populations and should therefore be considered when such CNS adverse effects occur during therapy.
已有多篇关于他汀类药物引起中枢神经系统（CNS）不良反应的报道。
一名79岁女性在开始服用阿托伐他汀10毫克/日约2.5周后出现妄想、焦虑和行为改变。此时患者未使用其他药物。治疗2个月后，患者停用阿托伐他汀，4天后症状完全缓解。
据我们所知，这是首例将妄想描述为与他汀类药物治疗相关症状之一的病例报告。我们的报告通过阿托伐他汀开始使用与症状发作之间的时间关系，以及治疗终止和随后症状消失，提示了阿托伐他汀引发的不良反应。使用纳伦霍药物不良反应概率量表评估因果关系显示，该不良事件为“可能”关联（评分，5分）。本报告强调了妄想作为他汀类药物治疗引起的中枢神经系统不良反应的可能性。他汀类药物常用于老年人群，因此在治疗期间出现此类中枢神经系统不良反应时应予以考虑。
